Current Utility of Staging Laparoscopy for Pancreatic and Peripancreatic Neoplasms
- 31 March 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American College of Surgeons
- Vol. 206 (3), 445-450
- https://doi.org/10.1016/j.jamcollsurg.2007.09.021
Abstract
The routine use of staging laparoscopy in patients with radiographically resectable pancreatic and peripancreatic neoplasms remains controversial. We reviewed a prospective database that identified 1,045 patients who underwent staging laparoscopy for radiographically resectable pancreatic or peripancreatic tumors between 1995 and 2005. Radiographic resectability was determined by review of radiographic reports, surgeons’ notes, and cross-sectional imaging studies. Factors were assessed for their association with the laparoscopic identification of radiographically occult unresectable disease. Recursive partitioning was used to build a decision tree, with laparoscopic identification of unresectable disease as the outcomes, including only patients since 1999 (modern imaging) and factors available preoperatively. Unresectable disease was identified laparoscopically in 145 of the 1,045 radiographically resectable patients (14%). Factors associated with radiographically occult unresectable disease included the time period of the study, whether imaging was performed at our institution (internal versus external imaging), primary site, histology, weight loss, and jaundice. Primary site (pancreatic versus nonpancreatic) was identified as the strongest predictor of yield. In patients with nonpancreatic tumors, the yield of laparoscopy was 4%. In patients with pancreatic tumors, the yield of laparoscopy was 14% overall, but was 8.4% in patients with internal imaging versus 17% in patients with external imaging (p < 0.01). This higher-risk subgroup was partitioned by the presence of weight loss, then by primary site within the pancreas. During the time period of this study, the yield of staging laparoscopy decreased and exceeded 10% only for patients with pancreatic adenocarcinoma. When high-quality cross-sectional imaging reveals no evidence of unresectable disease, routine staging laparoscopy may not be warranted for pancreatic or peripancreatic tumors other than presumed pancreatic adenocarcinoma.Keywords
This publication has 22 references indexed in Scilit:
- Initial Report of Laparoscopic Celiac Plexus Block for Pain Relief in Patients with Unresectable Pancreatic CancerJournal of the American College of Surgeons, 2006
- CA 19-9 Levels Predict Results of Staging Laparoscopy in Pancreatic CancerJournal of Gastrointestinal Surgery, 2005
- Therapeutic, prophylactic, and preresection applications of laparoscopic gastric and biliary bypass for patients with periampullary malignancySurgical Endoscopy, 2005
- Is there a role for staging laparoscopy in patients with locally advanced, unresectable pancreatic adenocarcinoma?Journal of Gastrointestinal Surgery, 2004
- Laparoscopic Staging and Subsequent Palliation in Patients With Peripancreatic CarcinomaAnnals of Surgery, 2003
- The Value of Laparoscopy in the Management of Ampullary, Duodenal, and Distal Bile Duct TumorsJournal of Gastrointestinal Surgery, 2002
- Diagnostic Laparoscopy for Periampullary and Pancreatic CancerJournal of Gastrointestinal Surgery, 2002
- Laparoscopy Predicts Metastatic Disease and Spares Laparotomy in Selected Patients With Pancreatic Nonfunctioning Islet Cell TumorsAnnals of Surgical Oncology, 2001
- Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypassJournal of the American College of Surgeons, 1999
- Diagnostic laparoscopy combined with laparoscopic ultrasonography in staging of cancer of the pancreatic head regionBritish Journal of Surgery, 1995